168,742 Shares in aTyr Pharma, Inc. $ATYR Acquired by Wellington Management Group LLP

Wellington Management Group LLP bought a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 168,742 shares of the company's stock, valued at approximately $510,000. Wellington Management Group LLP owned 0.19% of aTyr Pharma at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in shares of aTyr Pharma in the 4th quarter valued at about $881,000. Bank of America Corp DE bought a new position in aTyr Pharma in the 4th quarter valued at about $330,000. Jane Street Group LLC bought a new position in aTyr Pharma in the 4th quarter valued at about $720,000. Millennium Management LLC bought a new position in aTyr Pharma in the 4th quarter valued at about $1,332,000. Finally, Raymond James Financial Inc. bought a new position in aTyr Pharma in the 4th quarter valued at about $39,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock traded up $0.14 during mid-day trading on Friday, hitting $5.61. 3,928,278 shares of the stock were exchanged, compared to its average volume of 3,970,087. aTyr Pharma, Inc. has a 12 month low of $1.67 and a 12 month high of $7.29. The company has a 50-day simple moving average of $5.34 and a 200 day simple moving average of $4.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. The company has a market capitalization of $549.72 million, a P/E ratio of -7.01 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Sell-side analysts anticipate that aTyr Pharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATYR has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Wednesday, June 4th. Wells Fargo & Company raised their price target on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th. Wall Street Zen cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, Jefferies Financial Group raised their price target on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $23.25.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.